Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | UBE2N | P61088 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 7/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22339785 | 0.86 | KDM4E (0.60) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL5413550 | 0.85 | KDM4E (0.63) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL22339784 | 0.82 | KDM4E (0.66) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL28528958 | 0.82 | L3MBTL1 (0.61) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL949392 | 0.79 | KDM4E (0.61) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL949391 | 0.79 | KDM4E (0.61) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL946516 | 0.79 | HTR6 (0.74) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL3615171 | 0.78 | HTR6 (0.78) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL13302219 | 0.77 | KDM4E (0.63) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL16375238 | 0.76 | HTR6 (0.79) | KDM4EUBE2NL3MBTL1HTR6ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | KDM4E 3154/4885UBE2N 3308/4885L3MBTL1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.